{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:04:03Z","timestamp":1787731443826,"version":"build-2784847793"},"reference-count":92,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA125123"],"award-info":[{"award-number":["P30 CA125123"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA245903"],"award-info":[{"award-number":["R01 CA245903"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["U54 CA224076"],"award-info":[{"award-number":["U54 CA224076"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["U24 CA271076"],"award-info":[{"award-number":["U24 CA271076"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation","doi-asserted-by":"publisher","award":["T2021-018"],"award-info":[{"award-number":["T2021-018"]}],"id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015338","name":"National Cancer Institute Cancer Moonshot","doi-asserted-by":"publisher","award":["1U54CA232568-01"],"award-info":[{"award-number":["1U54CA232568-01"]}],"id":[{"id":"10.13039\/100015338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP220646"],"award-info":[{"award-number":["RP220646"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR170024"],"award-info":[{"award-number":["RR170024"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["P30 CA125123"],"award-info":[{"award-number":["P30 CA125123"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000043","name":"American Association for Cancer Research","doi-asserted-by":"publisher","award":["993916"],"award-info":[{"award-number":["993916"]}],"id":[{"id":"10.13039\/100000043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIH National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32GM136554"],"award-info":[{"award-number":["T32GM136554"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ymthe.2025.02.029","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T03:21:39Z","timestamp":1740021699000},"page":"1621-1641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["ZP4: A novel target for CAR-T cell therapy in triple negative breast cancer"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1788-9622","authenticated-orcid":false,"given":"Lauren K.","family":"Somes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan T.","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinpei","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego F.","family":"Chamorro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Shafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Z.","family":"Gad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lacey E.","family":"Dobrolecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Madaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Hoyos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.02.029_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.ymthe.2025.02.029_bib2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00404-015-3859-y","article-title":"An overview of triple-negative breast cancer","volume":"293","author":"Kumar","year":"2016","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.ymthe.2025.02.029_bib3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2025.02.029_bib4","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1158\/1078-0432.CCR-21-2600","article-title":"U.S. FDA drug approvals for breast cancer: a decade in review","volume":"28","author":"Arora","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.02.029_bib5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.02.029_bib6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3390\/cancers16010124","article-title":"Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential","volume":"16","author":"Chamorro","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2025.02.029_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2017.00267","article-title":"Engineering chimeric antigen receptor T-cells for racing in solid tumors: Don\u2019t forget the fuel","volume":"8","author":"Irving","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.02.029_bib8","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1158\/1535-7163.MCT-20-0385","article-title":"Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer","volume":"19","author":"Dees","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2025.02.029_bib9","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.02.029_bib10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T\u00a0cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.02.029_bib11","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.02.029_bib12","doi-asserted-by":"crossref","first-page":"991092","DOI":"10.3389\/fimmu.2022.991092","article-title":"Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma","volume":"13","author":"Chekol Abebe","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.02.029_bib13","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of t\u00a0cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.02.029_bib14","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-16-2083","article-title":"Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues","volume":"23","author":"Balakrishnan","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.02.029_bib15","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2010-05-283309","article-title":"The B-cell tumor-associated antigen ROR1 can be targeted with T\u00a0cells modified to express a ROR1-specific chimeric antigen receptor","volume":"116","author":"Hudecek","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.02.029_bib16","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2217\/fon.10.36","article-title":"Regulation of cancer germline antigen gene expression: Implications for cancer immunotherapy","volume":"6","author":"Akers","year":"2010","journal-title":"Future Oncol."},{"key":"10.1016\/j.ymthe.2025.02.029_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48064-w","article-title":"Cancer Testis Antigen Promotes Triple Negative Breast Cancer Metastasis and is Traceable in the Circulating Extracellular Vesicles","volume":"9","author":"Kannan","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.02.029_bib18","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/annonc\/mdq325","article-title":"Cancer-testis antigen expression in triple-negative breast cancer","volume":"22","author":"Curigliano","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ymthe.2025.02.029_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.154299","article-title":"The role of PRAME and NY-ESO-1 as potential therapeutic and prognostic biomarkers in triple-negative breast carcinomas","volume":"241","author":"See","year":"2023","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.ymthe.2025.02.029_bib20","doi-asserted-by":"crossref","first-page":"74378","DOI":"10.18632\/oncotarget.20102","article-title":"Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy","volume":"8","author":"Mirandola","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2025.02.029_bib21","doi-asserted-by":"crossref","first-page":"25356","DOI":"10.18632\/oncotarget.4516","article-title":"CXorf61 is a target for T\u00a0cell based immunotherapy of triplenegative breast cancer","volume":"6","author":"Paret","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2025.02.029_bib22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.molimm.2018.03.025","article-title":"Dysfunction of antigen processing and presentation by dendritic cells in cancer","volume":"113","author":"Bandola-Simon","year":"2019","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ymthe.2025.02.029_bib23","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1158\/2326-6066.CIR-22-0040","article-title":"Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor- Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors","volume":"10","author":"Kim","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2025.02.029_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.02.029_bib25","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","article-title":"TCR-engineered T\u00a0cells targeting E7 for patients with metastatic HPV-associated epithelial cancers","volume":"27","author":"Nagarsheth","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.02.029_bib26","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-cell transfer therapy targeting mutant KRAS in cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.02.029_bib27","article-title":"Tumor-associated antigen prediction using a single-sample gene expression state inference algorithm","volume":"4","author":"Yi","year":"2024","journal-title":"Cell Rep. Methods"},{"key":"10.1016\/j.ymthe.2025.02.029_bib28","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.cell.2020.10.036","article-title":"Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy","volume":"183","author":"Krug","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.02.029_bib29","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.3390\/genes12081266","article-title":"Zona Pellucida Genes and Proteins: Essential Players in Mammalian Oogenesis and Fertility","volume":"12","author":"Wassarman","year":"2021","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.ymthe.2025.02.029_bib30","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jri.2009.07.008","article-title":"Human zona pellucida glycoproteins: functional relevance during fertilization","volume":"83","author":"Gupta","year":"2009","journal-title":"J.\u00a0Reprod. Immunol."},{"key":"10.1016\/j.ymthe.2025.02.029_bib31","doi-asserted-by":"crossref","first-page":"619868","DOI":"10.3389\/fcell.2021.619868","article-title":"Human Zona Pellucida Glycoproteins: Binding Characteristics With Human Spermatozoa and Induction of Acrosome Reaction","volume":"9","author":"Gupta","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ymthe.2025.02.029_bib32","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.02.029_bib33","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","article-title":"Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer","volume":"173","author":"Hoadley","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.02.029_bib34","article-title":"Clinical Value of RNA Sequencing\u2013Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Network\u2014Breast Initiative","volume":"2","author":"Brueffer","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.ymthe.2025.02.029_bib35","first-page":"128","article-title":"Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis","volume":"4","author":"Garcia-Recio","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ymthe.2025.02.029_bib36","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.4049\/jimmunol.1202752","article-title":"Antibodies Targeting Human OX40 Expand Effector T Cells and Block Inducible and Natural Regulatory T Cell Function","volume":"191","author":"Voo","year":"2013","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2025.02.029_bib37","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1158\/1078-0432.CCR-17-1193","article-title":"Novel baff-receptor antibody to natively folded recombinant protein eliminates drug-resistant human b-cell malignancies in\u00a0vivo","volume":"24","author":"Qin","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.02.029_bib38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1480-9222-16-3","article-title":"Generation of a monoclonal antibody against the glycosylphosphatidylinositol-linked protein Rae-1 using genetically engineered tumor cells","volume":"16","author":"Hu","year":"2014","journal-title":"Biol. Proced. Online"},{"key":"10.1016\/j.ymthe.2025.02.029_bib39","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1158\/1078-0432.CCR-19-0187","article-title":"Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer","volume":"25","author":"Yeung","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.02.029_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218717","article-title":"A simplified workflow for monoclonal antibody sequencing","volume":"14","author":"Meyer","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.02.029_bib41","article-title":"Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape","volume":"12","author":"Ku","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.02.029_bib42","doi-asserted-by":"crossref","first-page":"1032403","DOI":"10.3389\/fimmu.2022.1032403","article-title":"The affinity of antigen-binding domain on the antitumor efficacy of CAR T\u00a0cells: Moderate is better","volume":"13","author":"Mao","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.02.029_bib43","doi-asserted-by":"crossref","first-page":"17608","DOI":"10.18632\/oncotarget.24807","article-title":"A Jurkat 76 based triple parameter reporter system to evaluate TCR functions and adoptive T\u00a0cell strategies","volume":"9","author":"Rosskopf","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2025.02.029_bib44","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2018-01-828343","article-title":"Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T\u00a0cells are associated with clinical outcomes in NHL","volume":"132","author":"Rossi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.02.029_bib45","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/humrep\/den047","article-title":"Native human zona pellucida glycoproteins: Purification and binding properties","volume":"23","author":"Chiu","year":"2008","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.ymthe.2025.02.029_bib46","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T\u00a0cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.02.029_bib47","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nri1632","article-title":"NFAT proteins: key regulators of T-cell development and function","volume":"5","author":"Macian","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.02.029_bib48","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ccell.2022.04.001","article-title":"Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia","volume":"40","author":"Leick","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2025.02.029_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ymthe.2025.02.029_bib50","article-title":"Inducible expression of interleukin-12 augments the efficacy of affinity-tuned chimeric antigen receptors in murine solid tumor models","volume":"14","author":"Yang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.02.029_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107186","article-title":"Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects","volume":"203","author":"Zhu","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ymthe.2025.02.029_bib52","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4049\/jimmunol.1800033","article-title":"Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3\u2013Targeted Chimeric Antigen Receptor\u2013Engineered T Cells in Hepatocellular Carcinoma","volume":"203","author":"Liu","year":"2019","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2025.02.029_bib53","article-title":"Antigen-dependent IL-12 signaling in CAR T\u00a0cells promotes regional to systemic disease targeting","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.02.029_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1165404","article-title":"IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models","volume":"14","author":"Shi","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.02.029_bib55","article-title":"GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma","volume":"10","author":"Gargett","year":"2022","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.02.029_bib56","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1158\/1078-0432.CCR-18-1811","article-title":"Eradication of neuroblastoma by T\u00a0cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15","volume":"25","author":"Chen","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.02.029_bib57","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T\u00a0cells resist dysfunction and mediate durable clearance of solid tumors and metastases","volume":"42","author":"Zhao","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.02.029_bib58","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/ijc.34843","article-title":"Novel chimeric antigen receptor-expressing T\u00a0cells targeting the malignant mesothelioma-specific antigen sialylated HEG1","volume":"154","author":"Kouro","year":"2024","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2025.02.029_bib59","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.3390\/cancers15123081","article-title":"CD28 and 41BB Costimulatory Domains Alone or in Combination Differentially Influence Cell Surface Dynamics and Organization of Chimeric Antigen Receptors and Early Activation of CAR T Cells","volume":"15","author":"Mez\u0151si-Csapl\u00e1r","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2025.02.029_bib60","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.omto.2020.06.016","article-title":"Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia","volume":"18","author":"Zhao","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2025.02.029_bib61","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg9721","article-title":"EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors","volume":"9","author":"Li","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2025.02.029_bib62","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.ymthe.2018.03.016","article-title":"Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector","volume":"26","author":"Smith","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.02.029_bib63","doi-asserted-by":"crossref","first-page":"1182409","DOI":"10.3389\/fimmu.2023.1182409","article-title":"Screening and characterization of the scFv for chimeric antigen receptor T\u00a0cells targeting CEA-positive carcinoma","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.02.029_bib64","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3390\/cancers12051075","article-title":"Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers","volume":"12","author":"Kailayangiri","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2025.02.029_bib65","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T\u00a0cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.02.029_bib66","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.molonc.2011.02.001","article-title":"The biology of cancer testis antigens: Putative function, regulation and therapeutic potential","volume":"5","author":"Fratta","year":"2011","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ymthe.2025.02.029_bib67","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.3389\/fimmu.2020.01568","article-title":"CAR T-Cell Cancer Therapy Targeting Surface Cancer\/Testis Antigens","volume":"11","author":"Jakobsen","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.02.029_bib68","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00262-011-1037-z","article-title":"MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing","volume":"60","author":"Bao","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2025.02.029_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2020.584024","article-title":"The Cancer\/Testis Antigen Gene VCX2 Is Rarely Expressed in Malignancies but Can Be Epigenetically Activated Using DNA Methyltransferase and Histone Deacetylase Inhibitors","volume":"10","author":"Jakobsen","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2025.02.029_bib70","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1158\/2767-9764.CRC-23-0566","article-title":"Epigenetic induction of cancer testis antigens and endogenous retroviruses at single-cell level enhances immune recognition and response in glioma","volume":"4","author":"Lai","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.ymthe.2025.02.029_bib71","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1093\/neuonc\/noac107","article-title":"Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell\u2013mediated toxicity against glioblastoma","volume":"24","author":"Ma","year":"2022","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.ymthe.2025.02.029_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179501","article-title":"Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells","volume":"12","author":"Siebenk\u00e4s","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.02.029_bib73","article-title":"Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T\u00a0cells in lung cancer","volume":"10","author":"Reppel","year":"2022","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.02.029_bib74","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26683-0","article-title":"Demethylating therapy increases anti-CD123 CAR T\u00a0cell cytotoxicity against acute myeloid leukemia","volume":"12","author":"El Khawanky","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.02.029_bib75","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/mt.2013.262","article-title":"Kinetics of Tumor Destruction by Chimeric Antigen Receptor-modified T Cells","volume":"22","author":"Anurathapan","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.02.029_bib76","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ymthe.2019.02.014","article-title":"EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells","volume":"27","author":"Kailayangiri","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.02.029_bib77","doi-asserted-by":"crossref","first-page":"e166028","DOI":"10.1172\/JCI166028","article-title":"IL-18-secreting CAR T\u00a0cells targeting DLL3 are highly effective in small cell lung cancer models","volume":"133","author":"Jaspers","year":"2023","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.02.029_bib78","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","article-title":"Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System","volume":"23","author":"Avanzi","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2025.02.029_bib79","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41551-022-00875-5","article-title":"CAR T\u00a0cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers","volume":"6","author":"Jin","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2025.02.029_bib80","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ymthe.2022.05.011","article-title":"Locally secreted BiTEs complement CAR T\u00a0cells by enhancing killing of antigen heterogeneous solid tumors","volume":"30","author":"Yin","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.02.029_bib81","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.02.029_bib82","doi-asserted-by":"crossref","first-page":"D956","DOI":"10.1093\/nar\/gkx1090","article-title":"LinkedOmics: Analyzing multi-omics data within and across 32 cancer types","volume":"46","author":"Vasaikar","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.02.029_bib83","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nmeth.3995","article-title":"A proposal for validation of antibodies","volume":"13","author":"Uhlen","year":"2016","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2025.02.029_bib84","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40425-018-0347-5","article-title":"CAR T\u00a0cell therapy for breast cancer: Harnessing the tumor milieu to drive T\u00a0cell activation","volume":"6","author":"Bajgain","year":"2018","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.02.029_bib85","article-title":"Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T\u00a0cell therapy for treatment of breast cancer","volume":"9","author":"Nalawade","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.02.029_bib86","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/mt.2014.47","article-title":"Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor","volume":"22","author":"Leen","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.02.029_bib87","doi-asserted-by":"crossref","first-page":"e3465","DOI":"10.21769\/BioProtoc.3465","article-title":"Semi-quantitative Determination of Protein Expression Using Immunohistochemistry Staining and Analysis: An Integrated Protocol","volume":"9","author":"Crowe","year":"2019","journal-title":"Bio. Protoc."},{"key":"10.1016\/j.ymthe.2025.02.029_bib88","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/bloodadvances.2021004583","article-title":"Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti\u2013PD-1\u2013based therapy","volume":"5","author":"Abbas","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.02.029_bib89","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1039\/C7LC00832E","article-title":"A deep conical agarose microwell array for adhesion independent three-dimensional cell culture and dynamic volume measurement","volume":"18","author":"Thomsen","year":"2017","journal-title":"Lab Chip"},{"key":"10.1016\/j.ymthe.2025.02.029_bib90","article-title":"Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma","volume":"11","author":"McKenna","year":"2023","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.02.029_bib91","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/9780470942390.mo120140","article-title":"Establishment of Patient-Derived Xenograft (PDX) Models of Human Breast Cancer","volume":"3","author":"Zhang","year":"2013","journal-title":"Curr. Protoc. Mouse Biol."},{"key":"10.1016\/j.ymthe.2025.02.029_bib92","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1158\/0008-5472.CAN-16-1911","article-title":"TEM8\/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer","volume":"78","author":"Byrd","year":"2018","journal-title":"Cancer Res."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625001194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625001194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T04:08:07Z","timestamp":1775102887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625001194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":92,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1525001625001194"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.02.029","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ZP4: A novel target for CAR-T cell therapy in triple negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.02.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society of Gene and Cell Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}